Insmed Incorporated

INSM

$36.99

+105.21% (1 year change)

Avg closing price

Price range

Market Cap

$3.75 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$42.5 Million

Total revenue in the last quarter.

Net Income

$-61.9 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-2.65

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-13.95x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-54.1 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

435

The number of full time employees.

Revenue & Earnings

Balance Sheet

Insmed Incorporated

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

News

Insmed (NASDAQ:INSM) Raised to “Buy” at BidaskClub

Insmed (NASDAQ:INSM) Raised to “Buy” at BidaskClub

BidaskClub upgraded shares of Insmed (NASDAQ:INSM) from a hold rating to a buy rating in a report published on Wednesday morning, BidAskClub reports. INSM has been the subject of a number of other ...

Dispatch Tribunal Dispatch Tribunal, 1 day ago
Insmed (INSM) Set to Announce Earnings on Thursday

Insmed (INSM) Set to Announce Earnings on Thursday

Insmed (NASDAQ:INSM) will be posting its quarterly earnings results before the market opens on Thursday, October 29th. Analysts expect Insmed to post earnings of ($0.59) per share for the quarter. ...

Daily Political Daily Political, 4 days ago
Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day

Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day

BRIDGEWATER, N.J., Sept. 30, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseas...

PR Newswire PR Newswire, 25 days ago